Can peptides be taken with semaglutide or tirzepatide?

Approved drugs come first in each group. This summarizes each compound’s own page; it isn’t medical advice, and a doctor or pharmacist can answer for a specific person.

From a product label 6

ExenatideApproved drug

LabelDon’t combine two GLP-1 drugs. Exenatide’s label rules out other exenatide products, and the weight labels for semaglutide and tirzepatide advise against adding any other GLP-1 drug.

LiraglutideApproved drug

LabelDon’t combine two GLP-1 drugs. Saxenda’s label advises against using it with other liraglutide products or any other GLP-1 drug, such as semaglutide or tirzepatide; Victoza’s, with other liraglutide products.

OrforglipronApproved drug

LabelDon’t combine two GLP-1 drugs. Foundayo’s label advises against using it with another GLP-1 drug, such as semaglutide or tirzepatide. In ATTAIN-MAINTAIN it replaced those injections rather than joining them.

SemaglutideApproved drug

LabelDon’t combine two GLP-1 drugs. Wegovy’s label advises against using it with other semaglutide products or any other GLP-1 drug, such as tirzepatide or liraglutide.

TirzepatideApproved drug

LabelDon’t combine two GLP-1 drugs. Zepbound’s label advises against using it with other tirzepatide products or any GLP-1 drug, such as semaglutide or liraglutide.

TriptorelinApproved drug

LabelNo published study has combined them, and no label lists an interaction. Trelstar’s label warns of raised blood sugar and calls for checks; an IVF trial gives semaglutide for 12 weeks, then a triptorelin trigger.

From human studies 1

CagrilintideHuman studies

TrialStudied mainly with semaglutide as CagriSema, both stepped up together to 2.4 mg. In East Asian adults, the pair cut weight 18.4% vs 11.9% on semaglutide alone at 68 weeks, if all stayed on treatment.

A precaution, not studied 23

GHRP-2Approved drug

PrecautionNo study has combined them. GHRP-2 raises hunger and growth hormone raises blood sugar, the opposite of what GLP-1 drugs do, so the two may work against each other.

MazdutideApproved drug

PrecautionIt already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up. No study has combined them; Wegovy’s label advises against using it with any other GLP-1 drug.

Melanotan 1Approved drug

PrecautionNo study has combined them, and no drug-interaction studies of afamelanotide exist (US label). Nausea is common with both, so it could add up.

PT-141Approved drug

PrecautionNo published study has combined them; a phase 2 weight-loss trial with tirzepatide hasn’t reported results. Both cause nausea and can slow stomach emptying, so stomach side effects may add up.

SS-31Approved drug

PrecautionNo study has combined them, and Forzinity’s label lists no interaction. Because it’s injected, the slower stomach emptying GLP-1 drugs cause shouldn’t affect its absorption.

TesamorelinApproved drug

PrecautionNo study has combined them, and no label lists an interaction. GLP-1 drugs lower blood sugar and weight, while tesamorelin can raise blood sugar and is weight neutral.

VIPApproved drug

PrecautionNo study has combined them, and no label lists an interaction. Diarrhea is a side effect of both VIP in the bloodstream and GLP-1 drugs.

ARA-290Human studies

PrecautionNo study has combined them. Both can lower blood sugar readings, so the effect of using them together is unknown.

CJC-1295 with DACHuman studies

PrecautionNo study has combined them, and no label lists an interaction. It keeps GH raised for days, which can push blood sugar up, while GLP-1 drugs lower it.

GHRP-6Human studies

PrecautionNo study has combined them. GHRP-6 is used for its hunger effect and FDA flags higher blood sugar, both the opposite of what GLP-1 drugs do, so the two may work against each other.

HexarelinHuman studies

PrecautionNo study has combined them. Hexarelin acts on the receptor for ghrelin, a hormone that raises hunger, and growth hormone raises blood sugar, so it may work against a GLP-1 drug.

IpamorelinHuman studies

PrecautionNo study has combined them, and no label lists an interaction. GLP-1 drugs curb appetite, while ipamorelin acts on the receptor for ghrelin, a hunger hormone.

LarazotideHuman studies

PrecautionNo study has combined them. GLP-1 drugs slow stomach emptying, which could shift when the delayed-release beads reach the small intestine relative to meals; this is untested.

Melanotan 2Human studies

PrecautionNo study has combined them. Both cause nausea and curb appetite, and bremelanotide’s label says it may slow stomach emptying and delay absorption of oral drugs.

MK-677Human studies

PrecautionNot yet studied: a phase 2 trial adding LUM-201 to oral semaglutide in 202 older adults with obesity is planned for 2027. MK-677 raises appetite and blood sugar, which GLP-1 drugs lower.

RetatrutideHuman studies

PrecautionIt already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up. No study has combined them; Zepbound’s label advises against tirzepatide with any GLP-1 drug.

SurvodutideHuman studies

PrecautionIt already acts on the GLP-1 receptor, so adding semaglutide or tirzepatide would double up. No study has combined them; Wegovy’s label advises against using it with any other GLP-1 drug.

TesofensineHuman studies

PrecautionNo study has combined them. Both reduce appetite and both raise resting heart rate (tesofensine about 7 beats per minute at 0.5 mg), so effects could add up.

CJC-1295 (no DAC)Preclinical

PrecautionNo study has combined them, and no label lists an interaction. GH-raising peptides can push blood sugar up, while GLP-1 drugs lower it.

HumaninPreclinical

PrecautionNo study has combined them. Humanin improved insulin action in rats, so added blood-sugar lowering is conceivable, but nothing has been tested.

IGF-1 DESPreclinical

PrecautionNo study has combined them. Both can lower blood sugar: GLP-1 drugs mainly with insulin or sulfonylureas, IGF-1 compounds directly, so lows could add up.

IGF-1 LR3Preclinical

PrecautionNo study has combined them. Both can lower blood sugar: GLP-1 drugs mainly with insulin or sulfonylureas, IGF-1 compounds directly, so lows could add up.

MOTS-cPreclinical

PrecautionNo study has combined them. Both can lower blood sugar, MOTS-c so far only in animals.

No study or report 38

CerebrolysinApproved drug

No studyNo study has combined them, and no label lists an interaction with GLP-1 drugs.

DSIPApproved drug

No studyNo study has combined them. The Deltaran label says no incompatibility with other medicines has been found, but none was tested with GLP-1 drugs.

GlutathioneApproved drug

No studyNo study has combined them, and the Italian label says no drug interactions have been described.

GonadorelinApproved drug

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

hCGApproved drug

No studyNo study has combined them, and no label lists an interaction. The urine-derived hCG labels say it hasn’t been shown to boost weight loss beyond calorie restriction.

L-CarnitineApproved drug

No studyNo study has combined them, and neither label lists an interaction. Both can cause nausea and diarrhea. A trial of a carnitine-containing supplement to protect muscle during GLP-1 weight loss is recruiting.

OxytocinApproved drug

No studyNo study has combined them, and no label lists an interaction. On its own, nasal oxytocin didn’t lower weight in an 8-week trial of 61 adults with obesity.

SelankApproved drug

No studyNo study has combined them. No interaction is known, but none has been looked for, and the Russian label lists none.

SemaxApproved drug

No studyNo study has combined them. The Russian labels expect no other drug to change how Semax is absorbed or cleared, but none was tested with GLP-1 drugs.

ThymalinApproved drug

No studyNo study has combined them. The Russian label lists no interaction with diabetes or weight-loss drugs.

Thymosin Alpha-1Approved drug

No studyNo study has combined them, and no label lists an interaction. Italy’s label advises caution only when it’s used with other immune-modulating medicines.

AOD9604Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

ArgirelineHuman studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

DihexaHuman studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

GHK-CuHuman studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

Kisspeptin-10Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

LL-37Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

MatrixylHuman studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

NAD+Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

SermorelinHuman studies

No studyNo study has combined them, and no label lists an interaction. The Irish test label notes that obesity and high blood sugar blunt the GH response to sermorelin.

SNAP-8Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

Thymosin Beta-4Human studies

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

5-Amino-1MQPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for; its mouse studies didn’t use GLP-1 drugs.

AdamaxPreclinical

No studyNo study has combined them, and Adamax itself has never been studied. No interaction is known because none has been looked for.

AHK-CuPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

BPC-157Preclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

CartalaxPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

EpithalonPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

Follistatin-344Preclinical

No studyNo study has combined them, and nothing is known about using follistatin alongside a GLP-1 drug. No label lists an interaction.

FOXO4-DRIPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

HGH Fragment 176-191Preclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

KPVPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

MGFPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

PE-22-28Preclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

PEG-MGFPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

PinealonPreclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

SLU-PP-332Preclinical

No studyNo study has combined them. No interaction is known, but none has been looked for.

TB-500Preclinical

No studyNo study has combined them. No interaction is known, but none has been looked for, and no label lists one.

Sources

Each answer comes from the compound’s own page, where its sources are listed.